Nifedipine Tablet, Extended Release
Product Images NDC 70518-2679

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 70518-2679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Nifedipine 30mg 70518 2679 00

This is a description of medication, specifically NIFEdipine with a 30mg dosage. The medication is in tablet form and is manufactured by Ingenus located in Fairfield, NJ with an NDC number of 70518-2679-00. The LOT number and expiration date are not available. The medication should be kept out of reach from children and should be swallowed whole, not bitten or divided. The package insert should be consulted for directions on use. The medication should be stored at a temperature between 20-26°C (63-77°F) with excursions allowed up to 15-30°C (59-86°F) as per USP guidelines. The remaining text is not legible.*

FDA Label Image

01 (Image 01)

FDA Label Image

02 (Image 02)

This text provides information about the side effects of Nifedipine extended-release tablets. The table shows the percentage of patients (N=707) who experienced adverse effects such as headache, fatigue, dizziness, constipation, and nausea. It also compares the percentage of patients who experienced similar effects while taking a placebo (N=266).*

FDA Label Image

03 (Image 03)

This is a table showing the percentage of adverse effects experienced by participants taking Nifedipine Capsules compared to those taking a placebo. The adverse effects listed include dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremor, peripheral edema, nervousness, mood changes, palpitations, dyspnea, cough, wheezing, nasal congestion, and sore throat. The number of participants in each group (N=226 for the Nifedipine group and N=235 for the placebo group) is also included in the table.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.